Search
forLearn
5 / 801 resultslearn TDM-105795
learn PTD-DBM
learn TeraCeutic™
learn PTT-6®
Research
5 / 1000+ resultsresearch Activation and regulation of the granulation tissue derived cells with stemness-related properties
Granulation tissue-derived cells can aid wound healing and serve as an alternative source of stem cells for tissue repair.
research Hair loss with levetiracetam in five patients with epilepsy
Levetiracetam may cause hair loss, which can potentially reverse with lower doses or stopping the drug.
research Ultrastructural and immunohistochemical characteristics of telocytes in human scalp tissue
Telocytes in the scalp may help with skin regeneration and maintenance.
research Levetiracetam in the Treatment of Idiopathic Generalized Epilepsies
Levetiracetam is widely used and generally well-tolerated for treating idiopathic generalized epilepsies, with tiredness as the main side effect.
research Valproate-Associated Transaminitis and Rhabdomyolysis
Valproic acid can cause muscle damage and liver issues, which improve after stopping the drug.
Community Join
5 / 1000+ resultscommunity GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
community Can GT20029's Become The Best Treatment Option?
The conversation discusses GT20029 as a potential hair loss treatment that could act like a cure by targeting androgen receptors in scalp hair follicles. Specific treatments mentioned include GT20029, with a user expressing hope that it could make male pattern baldness obsolete.
community GT20029 Big Phase 2 Update Results!
GT20029 showed promising results for hair growth in a Phase II trial, with the 1.0% twice-weekly regimen being the most effective. Some users expressed skepticism and humor about the product's effects and market availability.
community Looks like Kintor finished enrollment and dosing of phase 1 for gt20029 in China.
The conversation discusses the potential of a new hair loss treatment, GT20029, which targets androgen receptors in the scalp and is in phase 1 trials in China. Users express hope that this treatment will be more effective than current options like Minoxidil and Finasteride.
community Anagenic is trying to compound Gt20029
The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.